All In Biotech

Drug Trial Radar · NCT06561620

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

A Prospective Study of Befotertinib Adjuvant Therapy in Patients With Postoperative MRD-positive Non-small Cell Lung Cancer in Stage IA2-IB With High Risk Factors

Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

592

Planned (sponsor's estimate)

Start

May 1, 2024

Primary completion

May 1, 2027

Study completion May 1, 2029

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).

Conditions

  • 3-year Disease-free Survival

Interventions

  • BefotertinibDrug

    Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year disease-free survivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.